期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TKI治疗慢性粒细胞白血病慢性期的新目标转换 被引量：8

下载PDF
导出
摘要 第一代BCR-ABL酪氨酸激酶抑制剂(TKIs)伊马替尼是慢性粒细胞白血病(CML)慢性期的一线标准治疗。伊马替尼通过直接靶向作用于BCR-ABL激酶,极大的改善了CML病程。现在,第二代TKIs药物尼洛替尼和达沙替尼已被美国FDA批准为CML的一线治疗。2013年NCCN指南及ELN指南关于CML-CP治疗的疗效问题作了新的调整。该文主要就慢性粒细胞白血病慢性期一线治疗的新进展作一综述。
作者 陈莹莹 曾庆曙
机构地区 安徽医科大学第一附属医院血液内科
出处 《安徽医药》 CAS 2014年第11期2021-2024,共4页 Anhui Medical and Pharmaceutical Journal
关键词 慢性粒细胞性白血病 伊马替尼 尼洛替尼 达沙替尼
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献29

  • 1Druker BJ, Guilhot F, 0 ' Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J]. New England Journal of Medicine ,2006 ,355 (23) :2408 - 2417.
  • 2Eridani S, Wiedemann LM, Chan LC, et aL Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia [J]. Cytotechnology, 1987 , 1 ( I ) : 33 -36.
  • 3Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development [J] . Science, 1995 ,267 ( 5205 ) : 1782 - 1788.
  • 4Drukcr BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Ahl tyrosine kinase on the growth of Bcr - Abl positive cells [J]. Nature Medicine, 1996 ,2 (5) : 561 - 566.
  • 5Champlin RE, Golde OW. Chronic myelogenous leukemia: recent advancesD]. Blood, 1985 ,65 (5) : 1039 -1047.
  • 60' Brien SG, Guilhot F, Larson RA, et al, Imatinih compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia] 1] . New England Journal of Medicine,2003 ,348( 11) :994 -1004.
  • 7Vivona Tl , Lima LT, Rodrigues AC, et aL ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib [J] . Oncology letters, 20 14 ,7 ( 4 ) : 13 13.
  • 8Hochhaus A, 0' Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia[J]. Leukemia,2009 ,23 (6) : 1054 - 1106.
  • 9Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107 , a selective inhibitor of native and mutant Bcr-Abl [J] . Cancer cell, 2005 ,7 ( 2): 129 - 141.
  • 10Weisherg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL [J]. British Journal of Cancer, 2006 ,94( 12) : 1765 -1769.

二级参考文献123

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量：7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量：10
  • 3江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量：39
  • 4North American Association of Central Cancer Registries (2007) North American age-specific invasive cancer incidence rates, chronic myeloid leukemia,2000-2004, http ://www. cancer-rates, info/ naaccr/.
  • 5Laneuville P, Barnett M J, Belanger R, et al. Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol,2006,13:201-221.
  • 6O ' Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival ,low rate of transformation and increased rate of major molecular response(MMR) in patients with newly diagnosed chronic myeloid leukemia in chronic phase(CML-CP) treated with imatinib(IM). Blood ,2008,112 : 186a.
  • 7Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine Nature, 1973, 243(5405).
  • 8Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science, 1995,267(5205) : 1782-1788.
  • 9Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 1996,2(5):561-566.
  • 10Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001, 344(14) :1031-1037.

共引文献149

同被引文献75

  • 1AlmeidaMH,FogliattoL,CoutoD.ImportanceofadherencetoBCR-ABLtyrosine-kinaseinhibitorsinthetreatmentofchronicmyeloidleukemia[J].RevistaBrasileiradeHematologiaeHemot-erapia,2014,36(1):54-59.
  • 2DrukerBJ,O’BrienSG,GuilhotF,etal.Five-yearfollow-upofpatientsreceivingimatinibforchronicmyeloidLeukemia[J].NEnglJMed,2006,355(23):2408-2417.
  • 3CastagnettiF,TestoniN,LuattiS,etal.Deletionsofthederivativechromosome9donotinfluencetheresponseandtheoutcomeofchronicmyeloidleukemiainearlychronicphasetreatedwithima-tinibmesylate:GIMEMACMLworkingpartyanalysis[J].JClinOncol,2010,28(16):2748-2754.
  • 4SteinB,SmithBD.Treatmentoptionsforpatientswithchronicmy-eloidleukemiawhoareresistanttoorunabletotolerateimatinib[J].ClinicalTherapeutics,2010,32(5):804-820.
  • 5HardanI,StanevskyA,VolchekY,etal.TreatmentwithInterferonalphapriortodiscontinuationofImatinibinpatientswithchronicmyeloidleukemia[J].Cytokine,2012,57(2):290-293.
  • 6BrecciaM,AlimenaG.Thesignificanceofearly,majorandstablemolecularresponsesinchronicmyeloidleukemiaintheimatinibera[J].CriticalReviewsinOncology/Hematology,2011,79(2):135-143.
  • 7YilmazM,KantarjianH,JabbourE,etal.SimilarOutcomeofPa-tientsWithChronicMyeloidLeukemiaTreatedWithImatinibinorOutofClinicalTrials[J].ClinicalLymphomaMyelomaandLeu-kemia,2013,13(6):693-699.
  • 8JoergH,MicheleB,VerenaH,etal.Predictingcompletecytoge-neticresponseandsubsequentprogression-freesurvivalin2060patientswithCMLonimatinibtreatment:theEUTOSscore[J].Blood,2011,118(3):686-692.
  • 9StagnoF,VigneriP,RaimondoFD.Towardsaneedtoa“biologicalSokalrisk”intheeraoftyrosinekinaseinhibitorsinchoosingfront-linetherapyinchronicmyeloidleukemia[J].LeukemiaResearch,2012,36(7):803.
  • 10TaoZF,LiuBC,ZhaoYZ,etal.EUTOSscorepredictssurvivalandcytogeneticresponseinatientswithchronicphasechronicmyeloidleukemiatreatedwithfirst-lineimatinib[J].LeukemiaRe-search,2014,38(9):1030-1035.

引证文献8

二级引证文献13

安徽医药
2014年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部